Company Information:
Company Address:
5045 Orbitor Drive
Building 11, Suite 400
Mississauga, ON L4W 4Y4
Company’s Web Address: http://www.ymbiosciences.com
Industry Sector:
Fiscal Year:
Dividend:
Note: this section is not editable.
Please click here to report any inaccuracies.
Company Overview:
Company Products/Services/Markets:
Enter Company Products/Services Here
Strategy:
Describe Key Aspects of Company's Strategy Here
Competitors:
Enter Competitors Here
Industry Trends and News:
Enter Industry Trends and News Here
Acquisitions, Divestitures, Major Transactions, Spin-offs :
Enter Acquisitions, Divestiures, Major Transactions, Spin-offs Here
Management – Pros & Cons, Changes:
Enter Management - Pros & Cons, Changes Here
Financial Analysis:
Enter Financial Analysis Here
Valuation:
Enter Valuation Analysis and Valuation Ratios Here
| |
2007
|
2006
|
2005
|
| Price/Earnings |
|
|
|
| Price/EBITDA |
|
|
|
| Price/Pre-tax Income |
|
|
|
| Price/Revenue |
|
|
|
Investment Rationale:
Buy Rationale:
Enter Buy Rationale Here
Sell Rationale:
Enter Sell Rationale Here
Projected Financials:
Income Statement: (Paste Here)
Balance Sheet: (Paste Here)
Cash Flow Statement: (Paste Here)
Financial Ratios: (Paste Here)
Other: (Paste Here)
Discussion:
This area is for debates regarding different recommendations for this stock.
News:
|
Yahoo! Finance: YMI News
|
YM BIOSCIENCES PRESENTS DATA COMPARING MECHANISM OF ACTION FOR EGFR ANTIBODY, NIMOTUZUMAB TO CETUXIMAB AND PANITUMUMAB, AT THE AACR CENTENNIAL CONFERENCE ON TRANSLATIONAL CANCER MEDICINE 2008 (CNW Group)
|
Wall Street Media Presents Exclusive Videos from the Collins Stewart Fourth Annual Growth Conference (Business Wire)
|
Feuerstein's Biotech-Stock Mailbag: Delcath (at TheStreet.com)
|
Ym Biosciences Announces Fda Lifts Clinical Hold on Aerolef(R) and Clearance of a Phase II Clinical Trial (PR Newswire)
YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that the Clinical Hold imposed by the US Food and Drug Administration on the development of YM's AeroLEF® has been lifted.
|
Nimotuzumab Clinical Data Presented at Asco Annual Meeting (PR Newswire)
YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that clinical data from three clinical trials of its anti-cancer drug nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, were presented at the 2008 American Society of Clinical Oncology Annual Meeting being held in Chicago from May 30 to June 3, 2008.
|
NIMOTUZUMAB CLINICAL DATA PRESENTED AT ASCO ANNUAL MEETING (CNW Group)
YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that clinical data from three clinical trials of its anti-cancer drug nimotuzumab, a humanized monoclonal antibody that targets the epidermal growth factor receptor, were presented at the 2008 American Society of Clinical Oncology Annual Meeting being held in Chicago from May 30 to June 3, 2008.
|
Ym Biosciences Reports Nimotuzumab Nsclc Clinical Data at Asco Annual Meeting (PR Newswire)
YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that updated preliminary trial results, including survival, response rate and overall safety data, from its escalating dose trial of nimotuzumab were presented in a poster presentation on June 1st, 2008 at the Annual Meeting of the American Society of Clinical Oncology .
|
YM BIOSCIENCES REPORTS FISCAL THIRD QUARTER 2008 OPERATIONAL AND FINANCIAL RESULTS (CNW Group)
|
YM BIOSCIENCES ANNOUNCES SCHEDULE OF NIMOTUZUMAB PRESENTATIONS AT ASCO 2008 ANNUAL MEETING (CNW Group)
|
Ym Biosciences Announces Presentations for Aerolef(TM) at American Pain Society Annual Meeting (PR Newswire)
YM BioSciences Inc. , an oncology company that identifies, develops and commercializes differentiated products for patients worldwide, today announced that posters describing research conducted on its pain management product AeroLEF will be presented at The 27th Annual Scientific Meeting of the American Pain Society, which takes place May 8-10, 2008 in Tampa, Florida.
|
[video] News You Need: Wachovia, Disney (at TheStreet.com)
|
Thursday's Health Winners & Losers (at TheStreet.com)
|
YM BIOSCIENCES INC Financials (EDGAR Online Financials)
|
Tuesday's Late Winners & Losers (at TheStreet.com)
|
Friday's Health Winners & Losers (at TheStreet.com)
|
YM BioSciences Gets FDA Nod (at TheStreet.com)
|
See Also (links to blogs, forums, external sources, etc...):
